You're signed outSign in or to get full access.
Euclidean Capital LLC
Euclidean Capital LLC is a private investment office based in New York, NY. The firm manages investments on behalf of the Simons family and related parties. Founded post-2010, Euclidean Capital specializes in institutional asset management, primarily serving ultra-high-net-worth clients and family interests. As of June 2025, it manages approximately $306 million in public securities. The firm employs professionals skilled in portfolio management, asset allocation, and due diligence, but the precise employee count is not disclosed.
Investment Strategy
Euclidean Capital LLC invests across public equities and alternative assets on behalf of the Simons family, focusing on a diversified portfolio that includes broad index ETFs and select positions in healthcare and pharmaceutical companies. The firm actively rebalance positions, allocating heavily to international markets (notably VEU and INDA ETFs) and maintains a concentrated portfolio, exemplified by holding 97.9% of its securities in the top five positions. The strategy combines long-term growth with tactical shifts based on market conditions and sector opportunities.
Latest 13F Filing Activity
Euclidean Capital LLC filed their most recent 13F report on Jun 30, 2025 disclosing 11 equity positions with a total 13F market value of $306M. The fund increased holdings in Vanguard Intl Equity Index F, Ishares TR, Oric Pharmaceuticals Inc. among other positions. Euclidean Capital LLC reduced exposure to Rapt Therapeutics Inc., Surrozen Inc., PMV Pharmaceuticals Inc. among others.
Top Holdings
Equity Positions (11)
| Ticker | Security | Weight | Market Value | Shares | Avg Cost | Price | Change (QoQ) |
|---|---|---|---|---|---|---|---|
V VEU | VANGUARD INTL EQUITY INDEX F | 47.11% | $144.0M | 2,142,684 | $60.91 | $67.22 | +$23.2M |
I INDA | ISHARES TR | 44.17% | $135.0M | 2,425,144 | $42.12 | $55.68 | +$10.2M |
O ORIC | ORIC PHARMACEUTICALS INC | 3.28% | $10.0M | 989,410 | $27.05 | $10.15 | +$4.5M |
F FHTX | FOGHORN THERAPEUTICS INC | 2.42% | $7.4M | 1,573,761 | $17.64 | $4.70 | +$1.7M |
P PMVP | PMV PHARMACEUTICALS INC | 0.91% | $2.8M | 2,627,643 | $55.39 | $1.06 | -$78.8K |
Industry Allocation
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more